2. Search Result
Search Result
Results for "

pulmonary arterial hypertension

" in MedChemExpress (MCE) Product Catalog:

84

Inhibitors & Agonists

6

Peptides

2

Inhibitory Antibodies

3

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0750
    Monocrotaline
    40+ Cited Publications

    Crotaline

    		 Others Infection Metabolic Disease Cancer
    Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. [2][6][8].
    Monocrotaline
  • HY-14184
    Macitentan
    10+ Cited Publications

    ACT-064992

    		 Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan
  • HY-P99590
    Sotatercept
    2 Publications Verification

    ACE-011; MK-7962

    		 TGF-β Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
    Sotatercept
  • HY-A0126A
    Epoprostenol sodium
    1 Publications Verification

    Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan

    		 Endogenous Metabolite Apoptosis Cardiovascular Disease
    Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium
  • HY-P0012
    Aviptadil
    2 Publications Verification

    Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)

    		 SARS-CoV Infection Inflammation/Immunology
    Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil
  • HY-11103
    Sitaxsentan sodium
    2 Publications Verification

    IPI 1040 sodium; TBC11251 sodium

    		 Endothelin Receptor TGF-β Receptor Cardiovascular Disease Metabolic Disease
    Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
    Sitaxsentan sodium
  • HY-P1752
    Urocortin II, human

    		CRFR Bacterial Parasite NF-κB ERK Metabolic Disease
    Urocortin II, human is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. Urocortin II, human has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .
    Urocortin II, human
  • HY-109190
    Seralutinib
    2 Publications Verification

    GB002; PK10571

    		 PDGFR c-Fms c-Kit Cardiovascular Disease
    Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .
    Seralutinib
  • HY-10447
    Terameprocol

    EM-1421

    		 Survivin COX TNF Receptor Apoptosis Infection Inflammation/Immunology Cancer
    Terameprocol is an inhibitor targeting the Sp1 transcription factor, which can selectively inhibit the transcription of Sp1-dependent genes. Terameprocol exerts its effects by inhibiting Sp1-mediated gene transcription, such as reducing the expression of genes like CDC2, survivin and HMGB1, thereby arresting the cell cycle, inducing apoptosis, and suppressing the inflammatory response. Terameprocol exhibits anti-proliferative, pro-apoptotic, and anti-inflammatory activities and is currently mainly used in the research of diseases such as cancer and pulmonary arterial hypertension[1][2][3].
    Terameprocol
  • HY-109163
    Treprostinil palmitil

    INS-1009

    		 Prostaglandin Receptor Inflammation/Immunology Endocrinology
    Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease .
    Treprostinil palmitil
  • HY-13569A
    Beraprost sodium

    TRK-100; ML 1129 sodium

    		 Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    Beraprost sodium (TRK-100), a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium (TRK-100) is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost sodium (TRK-100) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Beraprost sodium
  • HY-109112
    Brilaroxazine

    RP5063

    		 Dopamine Receptor 5-HT Receptor Neurological Disease Inflammation/Immunology
    Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .
    Brilaroxazine
  • HY-154970A
    BMPR2-IN-1 TFA

    		TGF-β Receptor GSK-3 Cardiovascular Disease Neurological Disease Cancer
    BMPR2-IN-1 TFA is a selective BMPR2 inhibitor with a human BMPR2 IC50 of 506 nM and a Kd of 83.5 nM. BMPR2-IN-1 TFA functions as an ATP mimetic, forming hydrogen bonds with the BMPR2 kinase domain backbone and hydrophobic interactions with specific residues, and demonstrates high selectivity for BMPR2 over other kinases.BMPR2-IN-1 TFA can be used for the researches of cancer, pulmonary arterial hypertension and Alzheimer’s disease .
    BMPR2-IN-1 TFA
  • HY-103080
    CMF019

    		Apelin Receptor (APJ) Cardiovascular Disease
    CMF019 is an orally active, potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents . Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. CMF019 is promising for research of chronic diseases, such as, pulmonary arterial hypertension .
    CMF019
  • HY-101124
    Rodatristat ethyl

    KAR5585

    		 Tryptophan Hydroxylase 5-HT Receptor Cardiovascular Disease
    Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH) .
    Rodatristat ethyl
  • HY-170419
    APJ receptor agonist 10

    		Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 10 is an agonist of the APJ Receptor. APJ receptor agonist 10 can be used for research on pulmonary arterial hypertension .
    APJ receptor agonist 10
  • HY-150793
    SY-LB-57

    		TGF-β Receptor Cardiovascular Disease Neurological Disease
    SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension .
    SY-LB-57
  • HY-129851
    NTP42

    		Prostaglandin Receptor Cardiovascular Disease
    NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca 2+] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .
    NTP42
  • HY-P0012A
    Aviptadil acetate
    2 Publications Verification

    Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)

    		 SARS-CoV Infection Inflammation/Immunology
    Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil acetate
  • HY-128932
    Cefminox sodium
    1 Publications Verification

    MT-141

    		 Antibiotic Bacterial PPAR Prostaglandin Receptor PTEN Akt mTOR Infection Cardiovascular Disease Endocrinology
    Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .
    Cefminox sodium
  • HY-15472
    PRX-08066

    		5-HT Receptor p38 MAPK TGF-β Receptor FGFR Apoptosis Caspase Cardiovascular Disease Neurological Disease Cancer
    PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
    PRX-08066
  • HY-11095
    NPS 2390

    		mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase Cardiovascular Disease Neurological Disease
    NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
    NPS 2390
  • HY-90009S
    Tadalafil-d3

    IC-351-d3

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Tadalafil-d3 is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.
    Tadalafil-d3
  • HY-14184S
    Macitentan-d4

    ACT-064992-d4

    		 Isotope-Labeled Compounds Endothelin Receptor Apoptosis Cardiovascular Disease
    Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan-d4
  • HY-14184R
    Macitentan (Standard)

    ACT-064992 (Standard)

    		 Reference Standards Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan (Standard)
  • HY-160928
    Smurf1 modulator-1

    		E1/E2/E3 Enzyme Cardiovascular Disease
    Smurf1 modulator-1 (Compound 20) is a selective inhibitor for Smad ubiquitination regulatory factor 1 (Smurf1), with IC50 of 180 nM .
    Smurf1 modulator-1
  • HY-128593
    TPN171

    		Phosphodiesterase (PDE) Cardiovascular Disease
    TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) .
    TPN171
  • HY-174416
    Smurf1-IN-5

    		E1/E2/E3 Enzyme Cardiovascular Disease
    Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .
    Smurf1-IN-5
  • HY-149316
    Smurf1-IN-1

    		E1/E2/E3 Enzyme Cardiovascular Disease
    Smurf1-IN-1 is an orally active and selective inhibitor of specific E3 ubiquitin protein ligase 1 (SMURF1) with an IC50 of 92 nM. Smurf1-IN-1 has significant efficacy in rats model of pulmonary hypertension .
    Smurf1-IN-1
  • HY-162888
    WQ-C-401

    		PDGFR ERK Cardiovascular Disease
    WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .
    WQ-C-401
  • HY-P1752B
    Urocortin II, human acetate

    		CRFR Bacterial Parasite NF-κB ERK Metabolic Disease
    Urocortin II, human acetate is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .
    Urocortin II, human acetate
  • HY-76520
    Sitaxsentan

    IPI 1040; TBC-11251

    		 Endothelin Receptor TGF-β Receptor Cardiovascular Disease Metabolic Disease
    Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
    Sitaxsentan
  • HY-167906
    Lunamarine

    		Bacterial Phosphodiesterase (PDE) Metabolic Disease
    Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED) .
    Lunamarine
  • HY-154970
    BMPR2-IN-1

    		TGF-β Receptor Cancer
    BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC50 of 506 nM and a KD of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer .
    BMPR2-IN-1
  • HY-148670
    Pulmonary arterial hypertension agent-1

    		Drug Intermediate Prostaglandin Receptor Cardiovascular Disease
    Pulmonary arterial hypertension agent-1 (example 15) is a pulmonary arterial hypertension agent . Pulmonary arterial hypertension agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pulmonary arterial hypertension agent-1
  • HY-P3227
    Cyclo(Ala-Arg-Gly-Asp-Mamb)

    XJ735

    		 Integrin Inflammation/Immunology
    Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension research .
    Cyclo(Ala-Arg-Gly-Asp-Mamb)
  • HY-172234
    PF-06842874

    		CDK Cardiovascular Disease Cancer
    PF-06842874 is a CDK4/Cyclin D1 and CDK6/Cyclin D3 inhibitor (Ki values are 62 and 130 nM, respectively). PF-06842874 can be used in the research of pulmonary arterial hypertension and cancer .
    PF-06842874
  • HY-13569AR
    Beraprost sodium (Standard)

    TRK-100 (Standard); ML 1129 sodium (Standard)

    		 Reference Standards Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Beraprost sodium (Standard)
  • HY-14184A
    Macitentan n-butyl analogue

    		Endothelin Receptor Cardiovascular Disease Endocrinology
    Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan n-butyl analogue
  • HY-170419A
    APJ receptor agonist 10 free base

    		Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 10 free base is an agonist of the APJ Receptor. APJ receptor agonist 10 free base can be used for research on pulmonary arterial hypertension .
    APJ receptor agonist 10 free base
  • HY-172094
    AMPK-IN-6

    		AMPK Apoptosis Autophagy Cardiovascular Disease
    AMPK-IN-6 (compound 13a) is potent AMPK inhibitor with an IC50 value of 0.093 µM. AMPK-IN-6 induces apoptosis and inhibits autophagy. AMPK-IN-6 shows antiproliferative activity. AMPK-IN-6 has the potential for the research of pulmonary arterial hypertension .
    AMPK-IN-6
  • HY-117109R
    Amino Tadalafil (Standard)

    		Reference Standards Drug Derivative Others
    Amino Tadalafil (Standard) is the analytical standard of Amino Tadalafil. This product is intended for research and analytical applications. Amino Tadalafil is a structural analogue of Tadalafil (HY-90009A). Tadalafil is a potent inhibitor of PDE5 with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction .
    Amino Tadalafil (Standard)
  • HY-112704
    PDE5-IN-2

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC50 of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC50s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .
    PDE5-IN-2
  • HY-124051
    BAY-8040

    		Elastase Cardiovascular Disease Inflammation/Immunology
    BAY-8040 is a pyrimidopyridazine derivative which has inhibitory activity against human neutrophil elastase (HNE). BAY-8040 decreases cardiac remodeling and ameliorates cardiac function in a Monocrotaline (HY-N0750)-induced rat model for pulmonary arterial hypertension. BAY-8040 is promising for research of inflammatory pathologies and cardiopulmonary pathologies .
    BAY-8040
  • HY-105686
    FR-229934

    		Phosphodiesterase (PDE) Cardiovascular Disease
    FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction .
    FR-229934
  • HY-170435
    PDE5-IN-13

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .
    PDE5-IN-13
  • HY-90009R
    Nortadalafil (Standard)

    Demethyl Tadalafil (Standard)

    		 Reference Standards Phosphodiesterase (PDE) Cardiovascular Disease
    Nortadalafil (Standard) is the analytical standard of Nortadalafil. This product is intended for research and analytical applications. Nortadalafil , a new tadalafil (HY-90009A) analogue detected in health foods, is a PDE5 inhibitor. Nortadalafil is used in the research of erectile dysfunction (ED). Nortadalafil can be formed by closing the diketopiperazine ring in high yield. Nortadalafil is promising for research of pulmonary arterial hypertension [4] .
    Nortadalafil (Standard)
  • HY-155737
    ET receptor antagonist 1

    		Estrogen Receptor/ERR Cardiovascular Disease
    ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC50=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
    ET receptor antagonist 1
  • HY-155739
    ET receptor antagonist 3

    		Estrogen Receptor/ERR Cardiovascular Disease
    ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC50=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
    ET receptor antagonist 3
  • HY-168178
    Hsp110-STAT3 PPI-IN-2

    		HSP STAT Cardiovascular Disease
    Hsp110-STAT3 PPI-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 PPI-IN-2 can be used in pulmonary arterial hypertension (PAH) related research .
    Hsp110-STAT3 PPI-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: